Harrow, Inc. (HROW)

Market Cap	1.15B
Revenue (ttm)	212.86M
Net Income (ttm)	-21.70M
Shares Out	36.70M
EPS (ttm)	-0.61
PE Ratio	n/a
Forward PE	55.38
Dividend	n/a
Ex-Dividend Date	n/a

Volume	208,417
Open	31.58
Previous Close	31.66
Day's Range	31.29 - 31.88
52-Week Range	20.85 - 59.23
Beta	0.41
Analysts	Strong Buy
Price Target	59.00 (+88.08%)
Earnings Date	Aug 6, 2025

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye dr...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 382
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW
• Website: https://www.harrow.com

Financial Performance

In 2024, Harrow's revenue was $199.61 million, an increase of 53.32% compared to the previous year's $130.19 million. Losses were -$17.48 million, -28.39% less than in 2023.

Analyst Summary

According to 6 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $59.0, which is an increase of 88.08% from the latest price.

Price Target

$59.0

(88.08% upside)

Analyst Consensus: Strong Buy